Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 6,757 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CHANGE Study Clear all

Conditions: Leukemia, Acute Lymphoblastic Leukemia
Interventions: gene-modified T cells targeted; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Low-back Pain
Interventions: Digital program, Conventional physical therapy; Device · Other
Lead sponsor: Sword Health, SA; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: To Assess the Feasibility, Visualization Capability, and Optimal Dosing of ICG Fluorescence Imaging for Intraoperative Assessment of Knee Tissue Perfusion
Interventions: Intravenous administration of indocyanine green (SPY Agent Green) 2 mL of SPY Agent Green (5.0 mg dose), Intravenous administration of indocyanine green (SPY Agent Green) 3 mL of SPY Agent Green (7.5 mg dose), Intravenous administration of indocyanine green (SPY Agent Green) 4 mL of SPY Agent Green (10 mg dose), Intravenous administration of indocyanine green (SPY Agent Green)5 mL of SPY Agent Green (12.5 mg dose); Combination Product
Lead sponsor: Henry Ford Health System; Other
Eligibility: 14 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Secondhand Smoke, Air Trapping, Tobacco, Airflow Limitation, Hyperinflation, Obstructive Lung Disease
Interventions: Albuterol, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 80 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Smoking
Interventions: mTHS 2.2, mCC, NNS; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Anxiety
Interventions: Mayo Clinic Anxiety Coach; Device
Lead sponsor: Stephen Whiteside; Other
Eligibility: 7 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Unresectable Lung Non-Small Cell Carcinoma
Interventions: Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes; Other · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Age-Related Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years to 100 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anemia Associated With End Stage Renal Disease
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 26
States / cities: Anchorage, Alaska • Pine Bluff, Arkansas • Cerritos, California + 18 more

Conditions: COVID-19
Interventions: Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine; Drug · Biological
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 36
States / cities: Birmingham, Alabama • Davis, California • Irvine, California + 30 more

Conditions: Postoperative Nausea and Vomiting
Interventions: Intravenous fluid, D5LR or lactated ringers; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Stage IV Breast Cancer AJCC v6 and v7
Interventions: Dietary Intervention, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Dietary Supplement · Other · Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Presbyopia
Interventions: Raindrop Near Vision Inlay; Device
Lead sponsor: Eye Center of North Florida; Other
Eligibility: 41 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Panama City, Florida

Conditions: Gastrointestinal Disorders
Interventions: Gluten Healthy, Placebo; Dietary Supplement · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Healthy Individuals With no Periodontal Disease
Interventions: Nitrate-Supplemented Beet Juice, Nitrate-Depleted Beet Juice; Dietary Supplement
Lead sponsor: The Forsyth Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Falls, Osteopenia
Interventions: Wii Fit, Wait-List Control; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions: Abiraterone Acetate, Bicalutamide, Degarelix, Flutamide, Goserelin Acetate, Leuprolide Acetate, Nilutamide, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes, Type 1 Diabetes, Pregnancy, High Risk
Interventions: Mid-Ohio Food Farmacy (MOF+) produce delivery, Nutrition education with Dining with Diabetes (DWD), Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs; Dietary Supplement · Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Health Behavior
Interventions: SomaSignal Test Results; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 40 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Sleep Apnea, Obstructive, Healthy
Interventions: SLP swallowing exercises, myofunctional exercises; Other
Lead sponsor: Denise Dewald; Other
Eligibility: 40 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cancer
Interventions: Ipatasertib (capsule), Ipatasertib (tablet); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Staphylococcal Infections, Chronic Kidney Failure
Interventions: Staph aureus types 5 and 8 conjugate vaccine, placebo; Biological
Lead sponsor: Nabi Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
Interventions: Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug, Change platelet transfusion threshold, Full dose antithrombotics, Mechanical measures, Intermediate dose antithrombotic; Drug · Biological · Device
Lead sponsor: Maastricht University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Spinal Cord Injuries, Neurological Injury, Paralysis, Spasticity, Muscle
Interventions: Spinal Reflex Operant Down Conditioning; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Digital Care Program for Chronic Low Back Pain

ICG Fluorescence in Knee Arthroscopy Study

Secondhand Smoke Respiratory Health Study

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)

Youth Mayo Clinic Anxiety Coach Pilot Study

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Dark Adaptation in Participants With Age-Related Macular Degeneration

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting

Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer

A Study Raindrop Near Vision Inlay in Presbyopes Implanted in Corneal Pockets

Change in Permeability of the Small Intestine After Treatment With Gluten

The Effect of Nitrate Supplementation on Tongue Microbiome

Effect of a Wii Fit Intervention on Components of Fall Risk in Middle-aged Women

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes

Evaluating the Impact of SomaSignal Tests on Medical Management and Change in Risk in Patients at Higher Risk of Cardiovascular Disease: A Feasibility and an Adaptive Implementation Study

Swallowing in OSA & CPAP Intolerance

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease

Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia

Operant Conditioning of Spinal Reflexes Training System--Reflex Operant Down Conditioning